These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27976938)

  • 1. Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.
    Kantor DB; McDonald MC; Stenquist N; Schultz BJ; Smallwood CD; Nelson KA; Phipatanakul W; Hirschhorn JN
    Am J Respir Crit Care Med; 2016 Dec; 194(12):1552-1555. PubMed ID: 27976938
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
    Esquivel A; Busse WW; Calatroni A; Togias AG; Grindle KG; Bochkov YA; Gruchalla RS; Kattan M; Kercsmar CM; Khurana Hershey G; Kim H; Lebeau P; Liu AH; Szefler SJ; Teach SJ; West JB; Wildfire J; Pongracic JA; Gern JE
    Am J Respir Crit Care Med; 2017 Oct; 196(8):985-992. PubMed ID: 28608756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life long-term omalizumab therapy in children with severe allergic asthma.
    Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.
    Gill MA; Liu AH; Calatroni A; Krouse RZ; Shao B; Schiltz A; Gern JE; Togias A; Busse WW
    J Allergy Clin Immunol; 2018 May; 141(5):1735-1743.e9. PubMed ID: 28870461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma.
    Bourgoin-Heck M; Amat F; Trouvé C; Bernard A; Magny JP; Lambert N; Just J
    Pediatr Allergy Immunol; 2018 Feb; 29(1):90-93. PubMed ID: 28981968
    [No Abstract]   [Full Text] [Related]  

  • 8. Omalizumab in severe asthma: Evaluation of the clinical impact after its withdrawal.
    D de Sousa M; Ferreira C; Arrobas A
    Rev Port Pneumol (2006); 2017; 23(2):108-109. PubMed ID: 28209342
    [No Abstract]   [Full Text] [Related]  

  • 9. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Paggiaro PL
    J Investig Allergol Clin Immunol; 2017; 27(6):388-391. PubMed ID: 29199967
    [No Abstract]   [Full Text] [Related]  

  • 10. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
    Carrier C; Demoly P; Caimmi D
    Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.
    Deschildre A; Roussel J; Drumez E; Abou-Taam R; Rames C; Le Roux P; Pouessel G; Scalbert M; Bonnel C; Mitha S; Boileau S; Mordacq C; Thumerelle C; Labreuche J; Lejeune S; Marguet C
    Allergy; 2019 May; 74(5):999-1003. PubMed ID: 30481388
    [No Abstract]   [Full Text] [Related]  

  • 12. [Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].
    Romand P; Kelkel E; Saint-Raymond C; Glas N; Caillaud D; Devouassoux G
    Rev Mal Respir; 2016 May; 33(5):397-400. PubMed ID: 26346416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th1-related disease development during omalizumab treatment: Two cases with severe asthma.
    Hayashi H; Fukutomi Y; Mitsui C; Watai K; Tomita Y; Kamide Y; Sekiya K; Tsuburai T; Horita A; Saito I; Hasegawa Y; Taniguchi M
    Allergol Int; 2018 Jul; 67(3):405-407. PubMed ID: 29191372
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in the efficacy, safety, and tolerability of omalizumab after 1 year in Maltese patients with asthma.
    Gouder C; Asciak R; Montefort S
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):513-514. PubMed ID: 28283278
    [No Abstract]   [Full Text] [Related]  

  • 17. Omalizumab is effective and available for treatment of patients with severe allergic asthma in Poland.
    Zastrzeżyńska W; Gawlewicz-Mroczka A; Soja J; Sładek K; Musiał J; Bazan-Socha S
    Pol Arch Intern Med; 2017 Oct; 127(10):715-717. PubMed ID: 29162793
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of asthma by omalizumab: the role of CD4
    Amat F; Tallon P; Foray AP; Michaud B; Lambert N; Saint-Pierre P; Chatenoud L; Just J
    Clin Exp Allergy; 2016 Dec; 46(12):1614-1616. PubMed ID: 27770456
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.